Enlivex Therapeutics Files 2024/2023 Financial Statements
Ticker: ENLV · Form: 6-K · Filed: Mar 31, 2025 · CIK: 1596812
| Field | Detail |
|---|---|
| Company | Enlivex Therapeutics Ltd. (ENLV) |
| Form Type | 6-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, sec-filing, annual-report
TL;DR
Enlivex dropped its 2024/2023 audited financials. Check the numbers.
AI Summary
Enlivex Therapeutics Ltd. filed a Form 6-K on March 31, 2025, reporting its audited consolidated financial statements for the years ended December 31, 2024, and 2023. The filing includes statements of operations and comprehensive loss for the company, which is organized under the laws of Israel and previously operated as Bioblast Pharma Ltd. before changing its name on September 19, 2016.
Why It Matters
This filing provides investors with the official audited financial performance of Enlivex Therapeutics for the past two fiscal years, crucial for assessing the company's financial health and investment potential.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not introduce new risks.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Bioblast Pharma Ltd. (company) — Former company name
- March 31, 2025 (date) — Filing date
- December 31, 2024 (date) — Fiscal year end
- December 31, 2023 (date) — Fiscal year end
FAQ
What type of financial statements are included in this 6-K filing?
The filing includes audited consolidated financial statements as of December 31, 2024 and 2023, along with the related statements of operations and comprehensive loss.
When was Enlivex Therapeutics Ltd. previously known by another name?
Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd., with a name change occurring on September 19, 2016.
Under which jurisdiction is Enlivex Therapeutics Ltd. organized?
Enlivex Therapeutics Ltd. is organized under the laws of the State of Israel.
What is the principal executive office address for Enlivex Therapeutics Ltd.?
The principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel 7403618.
Does Enlivex Therapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
Enlivex Therapeutics Ltd. files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 31, 2025 regarding Enlivex Therapeutics Ltd. (ENLV).